Why the FDA’s Moves Matter for Cell and Gene Therapy

In a recent piece published by BioSpace, Anshul Mangal, CEO of Project Farma and President of PerkinElmer, shared a timely perspective on the FDA’s efforts to advance cell and gene therapy. Despite leadership changes and public scrutiny, the agency is showing renewed momentum through streamlined guidance, reduced regulatory burdens, and policy shifts designed to expand patient access.

In his piece, ‘How the FDA Is Accelerating Cell and Gene Therapy’s Next Chapter’, Anshul highlights how these actions are influencing investment, strengthening US competitiveness, and shaping the next phase of the advanced therapy sector.

Click here to read Anshul’s full opinion piece in BioSpace.